Patrick Kupelian
Papers
1
Total Citations
459
H-Index
1
About
Patrick Kupelian is a leading figure in radiation oncology, with a career focused on improving treatment outcomes for prostate cancer through rigorous clinical research. His key contributions center on risk-stratified therapy, comparative effectiveness, and the use of prostate-specific antigen (PSA) as a sensitive endpoint. His most influential work, the 2012 study from the Prostate Cancer Results Study Group, which has garnered over 459 citations, provided a landmark comparative analysis of PSA-free survival outcomes across low, intermediate, and high-risk prostate cancer patients treated with radical therapy. This study addressed a critical gap by systematically evaluating diverse treatment modalities using the most sensitive measurement tools available. Kupelian’s work has been instrumental in helping clinicians and patients make more informed decisions by clarifying how different risk groups respond to various interventions. Beyond this, his research has consistently advanced the understanding of dose escalation, hypofractionation, and the integration of advanced imaging in radiotherapy planning. Through his high-impact studies, Kupelian has shaped modern prostate cancer management, offering evidence-based guidance that continues to influence clinical practice and improve patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1